To the authors’ knowledge, this study has demonstrated, for the first time, a dual role of miR-22 in overcoming fulvestrant resistance, as both decreases and increases in miR-22 sensitize fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53. Here, TP53 is linked to breast cancer.